Open AccessDisruptive therapeutic innovation and the opportunity to eliminate a chronic disease The issue of chronic hepatitis C in Spain
Author(s) -
Conrado M Fernández Rodríguez
Publication year - 2017
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2017.5384/2017
Subject(s) - medicine , chronic hepatitis , quality adjusted life year , health technology , public health , chronic disease , cost effectiveness analysis , cost effectiveness , economic evaluation , actuarial science , public economics , health care , risk analysis (engineering) , intensive care medicine , economic growth , nursing , economics , virus , pathology , virology
Public funding decisions must be guided by criteria of scientific evidence, cost-effectiveness and economic evaluation. As an increase in health-effectiveness provided by therapeutic innovations can also substantially raise the cost, the cost-effectiveness analysis estimating this increase in the cost per unit of health gained compared to the previous technologies should be part of the economic evaluation. The measure of effectiveness most frequently used in health economic evaluations is the Quality Adjusted Life Year (QALY). Data from a Markov analysis presented by Turnes et al. in the last issue of this journal comparing two scenarios, pre-DAA and post-DAA in Spain is discussed in this document.